Royalty Pharma plc 4

Pablo G. Legorreta (CEO/Chairman of Royalty Pharma plc) received 65,216 Class A Ordinary Shares via equity award settlement and reported internal restructuring of exchangeable LP interests, with no open-market trades.

On August 5, 2026, Pablo G. Legorreta, CEO and Chairman of Royalty Pharma plc, reported an exempt acquisition under Rule 16b-3 of 65,216 Class A Ordinary Shares in connection with the settlement of equity performance awards, increasing his directly held Class A stake to 1,307,820 shares. In addition, the filing details extensive indirect holdings in Class A Ordinary Shares through various family trusts, entities, and family members, as well as significant LP interests in RPI US Partners 2019, LP that are exchangeable, via interests in Royalty Pharma Holdings Limited, into additional Class A Ordinary Shares for no additional consideration. On August 7, 2026, there was also an internal transfer coded as a disposition (G) of 30,000 LP interests in RPI US Partners 2019, LP, reflected against 300,000 Class A Ordinary Shares and various indirect vehicles, but the footnotes clarify that no LP interests are actually being exchanged at this time and that these represent structural exchange rights rather than open‑market sales, so the overall filing reflects compensation-related share issuance and internal ownership structuring rather than economic selling.

Filing Facts

CIK

1802768

Ticker

RPRX

Form

4

Source Type

fda

Accession

0001507678-26-000006

Alert Tier

5